Feature: Study Suggests 90% of Advanced Prostate Cancers May Have Anomaly that May Influence Treatment
View web version
New Approvals Bring Paradigm Shift in CLL
The approvals of obinutuzumab, ibrutinib, and idelalisib provide clinicians with new treatment options for patients with chronic lymphocytic leukemia (CLL).
Genetic Counseling Could Affect Treatment Options for PCa
Breast-conservation: APBI vs. Interstitial Brachytherapy
Latest News
Modified 2/1 Sunitinib Schedule May Be Safer in Renal Cell Carcinoma
Febuxostat Superior to Allopurinol for Prevention of Tumor Lysis Syndrome
Comparison of Two S-1 Plus Cisplatin Dosing Schedules Shows No Survival Advantage

Want to receive emails specific to your profession and specialty? Click here to complete your profile.

If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

To unsubscribe from the Weekly Highlights click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "email.cancertherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

© 2015 Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001